Related Experiment Video
Updated: Dec 7, 2025

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial
Chee Kay Cheung1, Jonathan Barratt1
1Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
Abstract:
The role of immunosuppression in the management of IgA nephropathy remains highly controversial. The Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial suggested that there was no benefit with the addition of immunosuppression to intensive supportive care, in terms of renal outcome. In this edition of Kidney International, Rauen et al. report long-term outcomes from the STOP-IgAN trial.
Related Concept Videos
Acute Kidney Injury III: Clinical Manifestations
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant III: Nursing Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Kidney Transplant I: Introduction

